Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia
European Respiratory Journal · 2026
DOI: 10.1183/13993003.02060-2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2026. Verfasst von Ahmad Aljohmani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dept of Molecular Pharmacology and Center for Human and Molecular Biology (ZHMB), Saarland University, Homburg, Germany. Hauptthemen laut MEDLINE: ADAM10 Protein, ADAM17 Protein, COVID-19, Pneumonia, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background
Pneumonia caused by viral or bacterial pathogens such as severe acute respiratory syndrome coronavirus 2 or Pseudomonas aeruginosa may result in life-threatening disease with a strong contribution of protease dysregulation. The present study aimed to systematically characterise the contribution of ADAM10 and ADAM17 on leukocytes and circulating exosomes to viral and bacterial pneumonia.
Methods
The analysis of coronavirus disease 2019 (COVID-19) and bacterial pneumonia patient samples was combined with in vivo experiments in conditional knockout animals lacking either ADAM10 or ADAM17 in leukocytes and cell culture experiments for mechanistic studies.
Results
Hospitalised bacterial pneumonia and COVID-19 patients displayed a severity dependent increase of ADAM10 and ADAM17 activity on exosomes. These exosomes caused pathophysiological changes of cardiomyocytes and the endothelial barrier. In a pre-clinical murine pneumonia model, we observed that leukocytes contributed to this increase in exosomal proteolytic activity. In the local environment of the lung, ADAM10 orchestrated a pro-inflammatory response with M1 macrophage polarisation, increased reactive oxygen species (ROS) generation, cytokine release, tissue damage and oedema formation, whereas ADAM17 seemed to dampen the initial inflammatory response to an anti-infective, ROS-balanced level.
Conclusion
Leukocytic ADAM10 and ADAM17 and their release on exosomes may constitute relevant regulatory elements in bacterial and viral pneumonia, with a potential contribution of exosomes to disease progression and systemic inflammatory responses. Therefore, the diagnostic, prognostic and therapeutic value of ADAM10 and ADAM17 should be evaluated in further preclinical and translational studies, addressing the changes of the immune response and exosomes as cargo vehicles both at local site and for the prevention of systemic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dept of Molecular Pharmacology and Center for Human and Molecular Biology (ZHMB), Saarland University, Homburg, Germany.
- Center for Molecular Signaling (PZMS), and Center for Gender-sensible Biology and Medicine (CGBM), Saarland University, Homburg, Germany.
- Dept for Internal Medicine V - Pulmonology, Allergology, Intensive Care Medicine, Saarland University, Homburg, Germany.
- Dept of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Be…
- Institute for Medical Microbiology and Hygiene, Saarland University, Homburg, Germany.
- Dept of Experimental Pharmacology, Saarland University, Homburg, Germany.
ORCID-Profile: Ahmad Aljohmani, Robert Bals
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Aljohmani, A., Herr, C., Witzenrath, M., Pätzold, L., Bischoff, M., Wartenberg, P., Boehm, U., Beisswenger, C., Tian, Q., Laschke, M. W., Hannig, M., Lehr, C. M., Bals, R., Schilling, O., & Yildiz, D. (2026). Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia. European Respiratory Journal. https://doi.org/10.1183/13993003.02060-2024
Vancouver
Aljohmani A, Herr C, Witzenrath M, Pätzold L, Bischoff M, Wartenberg P, et al. Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia. European Respiratory Journal. 2026. doi:10.1183/13993003.02060-2024
BibTeX
@article{Aljohmani2026,
author = {Aljohmani, Ahmad and Herr, Christian and Witzenrath, Martin and Pätzold, Linda and Bischoff, Markus and Wartenberg, Philipp and Boehm, Ulrich and Beisswenger, Christoph and Tian, Qinghai and Laschke, Matthias W and Hannig, Matthias and Lehr, Claus-Michael and Bals, Robert and Schilling, Oliver and Yildiz, Daniela},
title = {Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia},
journal = {European Respiratory Journal},
year = {2026},
doi = {10.1183/13993003.02060-2024}
}
EUVIMED